225P IKF-t045/ADVANCE: A phase II single-arm, open-label study of atezolizumab and derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements

作者：A. Vogel, T.O. Goetze, D.T. Waldschmidt, D. Zhang, M. Schuler, M. Bitzer, U. Pelzer, F. van Bömmel, T. Brunk, A. Weinmann, N. Schulte, Y-D. Ko, T. Habibzade, F. Knapp, S-E. Al-Batran, A. Saborowski · 发表于：Annals of Oncology · 年份：2026 · DOI：10.1016/j.annonc.2026.05.267 · 研究领域：Fibroblast Growth Factor Research、Cholangiocarcinoma and Gallbladder Cancer Studies、Liver physiology and pathology